In this video we discuss the results of a phase III trial that studied upfront high-dose chemotherapy plus autologous stem cell transplantation (ASCT) compared to chemotherapy alone and bortezomib in newly diagnosed multiple myeloma.
Michele Cavo, MD
Advertisement
Articles by Michele Cavo, MD
Advertisement
Latest Updated Articles
Upfront ASCT Still Best Option in Newly Diagnosed Multiple MyelomaPublished: June 23rd 2016 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
More Global Expertise and Talent Are Needed to Administer Cell Therapies
2
FDA Grants Priority Review to Enfortumab Vedotin Combo in MIBC Subset
3
Adaptive Treatment and Other Advances May Drive Radiotherapy Field Forward
4
Examining the Full Scope of Future Advancements in Radiation Oncology
5
